Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SORD | Q00796 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.52 |
| ▸ | HPGD | P15428 | 2/20 | 0.52 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | OGA | O60502 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | GBA1 | P04062 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18228454 | 1.00 | SORD (0.55) | SORDKDM4EALDH1A1HSD17B10HPGD | |
| SCHEMBL12597157 | 0.98 | KDM4E (0.55) | SORDKDM4EALDH1A1HSD17B10HPGD | |
| Hydrochloric Acid SCHEMBL10504874 | 0.96 | KDM4E (0.53) | SORDKDM4EALDH1A1HSD17B10HPGD | |
| SCHEMBL13806030 | 0.96 | SORD (0.55) | SORDKDM4EALDH1A1HSD17B10HPGD | |
| SCHEMBL15344981 | 0.86 | SORD (0.51) | SORDKDM4EALDH1A1HSD17B10HPGD | |
| SCHEMBL9488628 | 0.85 | SORD (0.56) | SORDSLC6A7OGAACHE | |
| SCHEMBL20899410 | 0.85 | SORD (0.52) | SORDKDM4EALDH1A1HSD17B10HPGD | |
| SCHEMBL27810118 | 0.84 | KDM4E (0.53) | SORDKDM4EALDH1A1HSD17B10HPGD | |
| Hydrochloric Acid SCHEMBL10410805 | 0.83 | SORD (0.55) | SORDSLC6A7OGAACHE | |
| SCHEMBL13033008 | 0.83 | KMT2A (0.56) | SORDKDM4EALDH1A1HSD17B10HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240270737-A1 | SMALL MOLECULAR INHIBITORS OF STING SIGNALING COMPOSITIONS AND METHODS OF USE | STINGINN INC. (US) | 2024-08-15 | — | — | US | disclosed |
| US-20230303573-A1 | 3-((Hetero-)Aryl)-8-Amino-2-Oxo-1,3-Diaza-Spiro-[4.5]-Decane Derivatives | Grünenthal GmbH (DE) | 2023-09-28 | — | — | US | disclosed |
| US-20230303573-A1 | 3-((Hetero-)Aryl)-8-Amino-2-Oxo-1,3-Diaza-Spiro-[4.5]-Decane Derivatives | Grünenthal GmbH (DE) | 2023-09-28 | — | — | US | disclosed |
| WO-2023163712-A1 | MODULATORS OF MYC FAMILY PROTO-ONCOGENE PROTEIN | NALO THERAPEUTICS (US) | 2023-08-31 | — | — | WO | disclosed |
| EP-3722284-A1 | 3-((HETERO-)ARYL)-8-AMINO-2-OXO-1,3-DIAZA-SPIRO-[4.5]-DECANE DERIVATIVES | Grünenthal GmbH (DE) | 2020-10-14 | — | — | EP | disclosed |
| EP-3402781-B1 | 3-((HETERO-)ARYL)-8-AMINO-2-OXO-1,3-DIAZA-SPIRO-[4.5]-DECANE DERIVATIVES | GRUENENTHAL GMBH (DE) | 2020-03-04 | — | — | EP | disclosed |
| CN-105814051-B | Tetrahydroimidazopyridine derivatives as modulators of TNF activity | UCB生物制药私人有限公司 | 2018-09-25 | — | — | CN | disclosed |
| WO-2017121647-A1 | 3-((HETERO-)ARYL)-8-AMINO-2-OXO-1,3-DIAZA-SPIRO-[4.5]-DECANE DERIVATIVES | Grünenthal GmbH (DE) | 2017-07-20 | — | — | WO | disclosed |
| EP-2834238-B1 | DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITORS | PFIZER (US) | 2017-02-01 | — | — | EP | disclosed |
| US-9296745-B2 | Diacylglycerol acyltransferase 2 inhibitors | PFIZER INC. (US) | 2016-03-29 | — | — | US | disclosed |
| US-20150087585-A1 | DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITORS | PFIZER INC. (US) | 2015-03-26 | — | — | US | disclosed |
| US-8680159-B2 | Bradykinin 1 receptor modulating compounds | GRUENENTHAL GMBH (DE) | 2014-03-25 | — | — | US | disclosed |
| WO-2013150416-A1 | DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITORS | PFIZER INC. (US) | 2013-10-10 | — | — | WO | disclosed |
| WO-2010062559-A1 | SUBSTITUTED PYRAZOLOQUINOLINES AND DERIVATIVES THEREOF | SCHERING CORPORATION (US) | 2010-06-03 | — | — | WO | disclosed |
| US-20090182140-A1 | Alicyclic Heterocyclic Compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-07-16 | — | — | US | disclosed |
| US-20090182140-A1 | Alicyclic Heterocyclic Compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-07-16 | — | — | US | disclosed |
| US-20090163469-A1 | Organic Compounds | NOVARTIS AG | 2009-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090182140-A1 | Alicyclic Heterocyclic Compound | CCR4, CCR1, HRH4 | SORD 3683/4885KDM4E 657/4885ALDH1A1 1767/4885 |
| US-20240270737-A1 | SMALL MOLECULAR INHIBITORS OF STING SIGNALING COMPOSITIONS AND METHODS OF USE | STING1, IRF3, MAVS | SORD 4839/4885KDM4E 2288/4885ALDH1A1 4812/4885 |
| US-20230303573-A1 | 3-((Hetero-)Aryl)-8-Amino-2-Oxo-1,3-Diaza-Spiro-[4.5]-Decane Derivatives | OPRK1, OPRD1, OPRL1 | SORD 1779/4885KDM4E 2919/4885ALDH1A1 337/4885 |
| US-20150087585-A1 | DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITORS | DGAT2, DGAT1, PLAAT2 | SORD 3843/4885KDM4E 2925/4885ALDH1A1 453/4885 |
| US-20090163469-A1 | Organic Compounds | PIK3C3, PIK3CA, PIK3CD | SORD 451/4885KDM4E 2761/4885ALDH1A1 1680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.